NCT05596266View on ClinicalTrials.gov

CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 25, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

October 25, 2025

Conditions
T-cell Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

CD5 CAR-T

CD5 CAR-T will be administered by I.V. infusion.

Trial Locations (1)

Unknown

RECRUITING

Xuanwu Hospital Capital Medical University, Beijing

All Listed Sponsors
collaborator

Baoding Children's Hospital

OTHER

lead

Xuanwu Hospital, Beijing

OTHER